The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...